# Vandria

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vandria

- Industry: Biotechnology
- Headquarters: Epalinges, Switzerland
- Website: www.vandria.com
- Total disclosed funding: $33M
- Latest round: Series A (Aug 21, 2024)
- Investors on record: 3

## About

Based in Epalinges, Switzerland, Vandria SA is a biopharmaceutical company that develops small molecule mitophagy inducers to treat age-related and chronic diseases. The company was co-founded by Johan Auwerx and Patrick Aebischer. In August 2024, Vandria SA raised CHF 10.3 million in Series A funding from Hevolution Foundation, and Dolby Family Ventures. The round was part of a larger CHF 28.3 million series A funding.
The company has created and patented new small molecules that focus on muscle tissue and the central nervous system (CNS).  Vandria is in the process of preparing for IND (investigational new drug) submission for lead candidates that have demonstrated positive results both in the laboratory and in living organisms. The targeted diseases include mild cognitive impairment, ALS (Amyotrophic Lateral Sclerosis), Parkinson's disease (PD) for the CNS, and sporadic body myositis and sarcopenia for muscle-related conditions..

## Funding rounds

- Series A, Aug 21, 2024, $12M — Dolby Family Ventures, Hevolution Foundation
- Series A, Dec 14, 2023, $21M — +ND Capital

## Investors

- +ND Capital (https://capitalatlas.ai/funds/nd-capital) — Series A
- Dolby Family Ventures (https://capitalatlas.ai/funds/dolby-family-ventures) — Series A
- Hevolution Foundation — Series A